PATENT CLAIM ANALYSIS

Application Number: 16061279
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["514", "259410"]

Abstract:
Disclosed in the present invention are a crystalline Form of pyrido[1,2-a]pyrimidone analog, a preparation method therefor and an intermediate thereof,

Claim (Index 35):
A method for treating PI3K kinase-related diseases, comprising administering a therapeutically effective amount of crystalline forms of Compound 1 or the salts thereof of  claim 22  to patients in need, wherein the PI3K kinase-related disease is preferably selected from cancer, more preferably colon cancer and gastric cancer.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 94.0
- Lexical Diversity: 1.08333
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15504018', '15539147', '16331915', '12559927', '16343165']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7893864743927942
- 35 USC 102 Novelty (BERT): 0.5297371349637857
- Combined Prediction Score: 0.7634215404498934
- Mean Citation Score: 323.776176
- Max Citation Score: 338.88705
- Similarity Product: 170.40541291519403

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test